Balancing cost:benefit in ‘well-treated’ malignancies

30 April 2018

Oncologists and pharmaceutical companies are increasingly discussing the cost:benefit ratio of cancer treatments. It is a topic that is under the microscope, particularly now, with the advent of immunotherapies. In our latest whitepaper, Jeremy Smith (Director of Client Strategy at THE PLANNING SHOP) discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still promoting R&D.